Inspira Technologies Oxy B. H. N. Ltd. is a specialty medical device company engaged in the research development manufacturing and commercialization of proprietary life support technologies. The company aims to replace invasive mechanical ventilation with systems that oxygenate blood directly and remove carbon dioxide while allowing patients to remain awake. Its core technology platforms include the INSPIRA ART100 cardiopulmonary bypass system the HYLA blood sensor and the VORTX orbiting blood oxygenation device. Inspira Technologies Oxy B. H. N. Ltd. is headquartered in Ra’anana Israel and maintains a team of engineers clinicians and regulatory specialists to advance its products toward commercialization. The firm was founded in 2018 and has undergone several name changes reflecting its evolving focus on life support solutions. It has raised capital through private placements and public offerings to fund research development and regulatory efforts. Inspira Technologies Oxy B. H. N. Ltd. operates as an emerging growth company and a foreign private issuer which provides certain reporting exemptions under U. S. securities laws.

Revenue is derived principally from the sale of the INSPIRA ART100 system and its associated disposable components such as tubing oxygenators and cannulas. The company also plans to commercialize the HYLA blood sensor as a standalone monitor and as an integrated module within the ART100 platform. Disposable kits are expected to generate recurring revenue because each patient treatment requires a new set of single use components. Inspira Technologies Oxy B. H. N. Ltd. has already recorded its first product sales and has received binding purchase orders from distributors and governmental bodies that anticipate revenue recognition upon delivery and installation. Additional income may arise from licensing agreements strategic collaborations and potential service contracts related to device maintenance and training. The company reported its first revenue in 2025 following the delivery of INSPIRA ART100 systems to a U. S. hospital under a purchase order with Glo Med. Additional purchase orders from a African ministry of health and a European governmental authority are expected to convert into revenue during the 2026 fiscal year as budget allocations are finalized. Inspira Technologies Oxy B. H. N. Ltd. also anticipates revenue from the sale of disposable kits which are designed to be compatible with multiple extracorporeal circuits.

The medical device market for respiratory and critical care support is dominated by large multinational corporations such as Medtronic Philips Boston Scientific ResMed Masimo Becton Dickinson and Getinge. Inspira Technologies Oxy B. H. N. Ltd. competes by offering proprietary technologies that avoid the lung damaging effects of traditional ventilators and enable real time blood monitoring. Key differentiators include the VORTX orbiting blood oxygenation system which eliminates fiber membranes the dual lumen cannula that allows single incision access and the HYLA sensor that provides continuous oxygen and carbon dioxide data. The company holds a growing patent portfolio with multiple granted patents in the United States Japan and Israel and has obtained ISO 13485 certification for its quality management system. Strategic partnerships with hospitals distributors and OEM suppliers such as Terumo Cardiovascular and Glo Med enhance its ability to navigate regulatory pathways and achieve market adoption. The global respiratory care devices market is projected to exceed sixteen billion dollars by 2029 driven by aging populations rising respiratory disease prevalence and increased ICU admissions. Inspira Technologies Oxy B. H. N. Ltd. positions itself to capture a share of this growth by offering a lower cost alternative that reduces patient length of stay and associated complications. Its technology does not require patient sedation or intubation which may decrease hospital resource utilization and improve patient experience. The firm’s intellectual property strategy includes filing new patent applications maintaining existing patents and defending its innovations against potential infringement.

Inspira Technologies Oxy B. H. N. Ltd. serves hospitals medical centers health systems group purchasing organizations and distributors in North America Europe Israel Africa and other regions. Specific customers and partners named in the filing include Glo Med Innovimed WAAS Group Bepex CIO MED GROUP Clalit Health Services Westchester Medical Center Sheba Hospital Beilinson Hospital Terumo Cardiovascular Ennocure Zriha Medical Ltd and Bites Learning Ltd. Distribution agreements cover territories such as Texas New York Florida and countries including Spain Portugal Poland Czech Republic Slovakia and various nations in Central America and Africa. The company also collaborates with leading academic medical centers for clinical evaluations and has secured purchase orders from governmental health authorities in Africa and from a privately held entity based outside the United States. Collaboration agreements with firms like Ennocure and Zriha Medical Ltd aim to reduce infection risks associated with cannula insertion and to enhance product functionality. Inspira Technologies Oxy B. H. N. Ltd. also works directly with hospitals such as Westchester Medical Center and Sheba Hospital to conduct clinical trials and generate real world evidence. The company’s distribution partners include regional specialists such as Innovimed for Eastern Europe and the Middle East WAAS Group for the Iberian Peninsula and CIO MED GROUP for Central America. In the United States Glo Med serves as the primary distributor for multiple states and has committed to purchase thousands of INSPIRA ART100 systems and associated disposables over multi year periods.